07:00 , May 6, 2004 |  BC Extra  |  Financial News

Axys sells DPII stake

Axys (South San Francisco, Calif.) raised $36.1 million through the sale of its full stake of 7.2 million shares in Discovery Partners (DPII) in a deal underwritten by SG Cowen; Merriman Curhan Ford; and Roth...
08:00 , Mar 15, 2004 |  BioCentury  |  Finance

Ebb & Flow

While VCs continue to pour money into no research-development only companies, drug reprofilers and other fast track business models, at least one NRDO got some push-back from the public markets. After competing its road show...
08:00 , Mar 11, 2004 |  BC Extra  |  Financial News

Axys to sell DPII stake

Axys (South San Francisco, Calif.) plans to offer its full stake of 7.2 million shares of Discovery Partners (DPII) in a deal underwritten by SG Cowen; Merriman Curhan Ford; and Roth Capital. Axys received the...
08:00 , Mar 10, 2003 |  BioCentury  |  Finance

Ebb & Flow

For those who think an M&A announcement represents the endgame for a biotech company, last week's maneuverings surrounding the proposed takeouts of Corvas (CVAS) and Oxford GlycoSciences (LSE:OGS; OGSI) provides notice that a deal may...
08:00 , Nov 18, 2002 |  BioCentury  |  Strategy

Integration II

In 1999, when it became abundantly clear that having the suffix "omics" in the boilerplate did not constitute a business plan, many companies began morphing into therapeutic plays. This is not an easy transition, and...
08:00 , Nov 18, 2002 |  BioCentury  |  Strategy

Headcount shifts

Headcount shifts Start transition Then Now Notes ArQule April 1999 ~150 employees ~400 employees In first nine months of 2001, increased headcount from 255 to 361, including computational scientists from Camitro acquisition Celera Early 2001...
07:00 , Oct 14, 2002 |  BC Week In Review  |  Company News

Celera Genomics Group, Bayer deal

CRA purchased all rights and compounds under a 1994 asthma deal between BAY and Axys, which CRA acquired last year. CRA also will receive study data and relevant IP relating to oral treatments for asthma...
07:00 , Oct 14, 2002 |  BioCentury  |  Product Development

Celera not inhibited by triptases

The triptase inhibition program of Bayer AG and the former Axys Pharmaceuticals Inc. has run into multiple problems with formulation and toxicology since it was started in 1994. But Celera Genomics Group, which acquired Axys...
07:00 , Oct 8, 2002 |  BC Extra  |  Top Story

Celera buys asthma compounds

CRA purchased all rights and compounds under a 1994 asthma deal between Bayer (BAY; FSE:BAYG) and Axys , which CRA acquired last year. CRA also will receive study data and relevant IP relating to oral...
08:00 , Mar 4, 2002 |  BioCentury  |  Strategy

CAT catches a change artist

Cambridge Antibody Technology Group plc has defied conventional wisdom by choosing a new CEO with no experience in moving drugs through the clinic to market. Instead, the antibody company last week named Peter Chambre, who...